The FDA recently approved Reblozyl.
Reblozyl reduced blood transfusion requirements by 33% in ~20% of patients, and by 50% in ~8%. A typical dose of Reblozyl consists of 1 mg of the drug for a kilogram of the patient's weight. A 75 mg vial of Reblozyl will be available at a wholesale acquisition cost of US$10,323.53 per vial. Dosing is every three weeks. This cost does not include hospital markup or admin fee.
General Comments / Chat, page-52
-
- There are more pages in this discussion • 11,322 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
-0.030(1.75%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.73 | $1.68 | $119.9K | 70.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3012 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 6382 | 1 |
View Market Depth
| Last trade - 15.07pm 03/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |